Efficacy of single versus four repeated doses of praziquantel against Schistosoma mansoni infection in school-aged children from Côte d'Ivoire based on Kato-Katz and POC-CCA: An open-label, randomised controlled trial (RePST)

Pytsje T Hoekstra, Miriam Casacuberta-Partal, Lisette van Lieshout, Paul L A M Corstjens, Roula Tsonaka, Rufin K Assaré, Kigbafori D Silué, Aboulaye Meité, Eliézer K N'Goran, Yves K N'Gbesso, Abena S Amoah, Meta Roestenberg, Stefanie Knopp, Jürg Utzinger, Jean T Coulibaly, Govert J van Dam, Pytsje T Hoekstra, Miriam Casacuberta-Partal, Lisette van Lieshout, Paul L A M Corstjens, Roula Tsonaka, Rufin K Assaré, Kigbafori D Silué, Aboulaye Meité, Eliézer K N'Goran, Yves K N'Gbesso, Abena S Amoah, Meta Roestenberg, Stefanie Knopp, Jürg Utzinger, Jean T Coulibaly, Govert J van Dam

Abstract

Background: Preventive chemotherapy with praziquantel (PZQ) is the cornerstone of schistosomiasis control. However, a single dose of PZQ (40 mg/kg) does not cure all infections. Repeated doses of PZQ at short intervals might increase efficacy in terms of cure rate (CR) and intensity reduction rate (IRR). Here, we determined the efficacy of a single versus four repeated treatments with PZQ on Schistosoma mansoni infection in school-aged children from Côte d'Ivoire, using two different diagnostic tests.

Methods: An open-label, randomized controlled trial was conducted from October 2018 to January 2019. School-aged children with a confirmed S. mansoni infection based on Kato-Katz (KK) and point-of-care circulating cathodic antigen (POC-CCA) urine cassette test were randomly assigned to receive either a single or four repeated doses of PZQ, administered at two-week intervals. The primary outcome was the difference in CR between the two treatment arms, measured by triplicate KK thick smears 10 weeks after the first treatment. Secondary outcomes included CR estimated by POC-CCA, IRR by KK and POC-CCA, and safety of repeated PZQ administration.

Principal findings: During baseline screening, 1,022 children were assessed for eligibility of whom 153 (15%) had a detectable S. mansoni infection, and hence, were randomized to the standard treatment group (N = 70) and the intense treatment group (N = 83). Based on KK, the CR was 42% (95% confidence interval (CI) 31-52%) in the standard treatment group and 86% (95% CI 75-92%) in the intense treatment group. Observed IRR was 72% (95% CI 55-83%) in the standard treatment group and 95% (95% CI 85-98%) in the intense treatment group. The CR estimated by POC-CCA was 18% (95% CI 11-27%) and 36% (95% CI 26-46%) in the standard and intense treatment group, respectively. Repeated PZQ treatment did not result in a higher number of adverse events.

Conclusion/significance: The observed CR using KK was significantly higher after four repeated treatments compared to a single treatment, without an increase in adverse events. Using POC-CCA, the observed CR was significantly lower than measured by KK, indicating that PZQ may be considerably less efficacious as concluded by KK. Our findings highlight the need for reliable and more accurate diagnostic tools, which are essential for monitoring treatment efficacy, identifying changes in transmission, and accurately quantifying the intensity of infection in distinct populations. In addition, the higher CR in the intense treatment group suggests that more focused and intense PZQ treatment can help to advance schistosomiasis control.

Trial registration: www.clinicaltrials.gov NCT02868385.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Trial profile.
Fig 1. Trial profile.
a. Sample (urine and/or stool) not provided. b. Intention-to-treat analysis.
Fig 2. Prevalence over time (with corresponding…
Fig 2. Prevalence over time (with corresponding pointwise 95% confidence intervals) estimated from the mixed effects logistic regression model.
Data pertain to (a) triplicate Kato-Katz (KK) thick smears from a single stool sample and (b) single point-of-care circulating cathodic antigen (POC-CCA) urine test in the standard treatment group (single dose of PZQ, solid line) and the intense treatment group (four doses of PZQ at W0, W2, W4, and W6, dashed line).
Fig 3. Intensity of infection.
Fig 3. Intensity of infection.
Data are based on triplicate Kato-Katz (KK) thick smears from a single stool sample (a, b) and single point-of-care circulating cathodic antigen (POC-CCA) urine test (c, d) in the standard treatment group (single dose of PZQ) and the intense treatment group (four doses of PZQ at W0, W2, W4, and W6).

References

    1. WHO. Schistosomiasis 2019 [Available from: ].
    1. Hotez PJ, Alvarado M, Basáñez MG, Bolliger I, Bourne R, Boussinesq M, et al. The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis. 2014;8(7):e2865 10.1371/journal.pntd.0002865 .
    1. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet. 2014;383(9936):2253–64. 10.1016/S0140-6736(13)61949-2
    1. McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou XN. Schistosomiasis. Nat Rev Dis Primers. 2018;4(1):13 10.1038/s41572-018-0013-8 .
    1. WHO. Schistosomiasis: progress report 2001–2011 and strategic plan 2012–2020 Geneva: World Health Organization; 2013.
    1. French MD, Evans D, Fleming FM, Secor WE, Biritwum NK, Brooker SJ, et al. Schistosomiasis in Africa: improving strategies for long-term and sustainable morbidity control. PLoS Negl Trop Dis. 2018;12(6):e0006484 10.1371/journal.pntd.0006484 .
    1. Andrade G, Bertsch DJ, Gazzinelli A, King CH. Decline in infection-related morbidities following drug-mediated reductions in the intensity of Schistosoma infection: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2017;11(2):e0005372 10.1371/journal.pntd.0005372 .
    1. WHO. Helminth control in school age children: a guide for managers of control programmes - 2nd ed. Geneva: World Health Organization; 2011.
    1. WHO. Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers Geneva: World Health Organization; 2006.
    1. Knopp S, Becker SL, Ingram KJ, Keiser J, Utzinger J. Diagnosis and treatment of schistosomiasis in children in the era of intensified control. Expert Rev Anti Infect Ther. 2013;11(11):1237–58. 10.1586/14787210.2013.844066 .
    1. Keiser J, N'Guessan NA, Adoubryn KD, Silué KD, Vounatsou P, Hatz C, et al. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial. Clin Infect Dis. 2010;50(9):1205–13. 10.1086/651682
    1. King CH, Olbrych SK, Soon M, Singer ME, Carter J, Colley DG. Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review. PLoS Negl Trop Dis. 2011;5(9):e1321 10.1371/journal.pntd.0001321 .
    1. Zwang J, Olliaro P. Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis. Parasit Vectors. 2017;10(1):47 10.1186/s13071-016-1958-7 .
    1. Zwang J, Olliaro PL. Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis: a meta-analysis of comparative and non-comparative clinical trials. PLoS Negl Trop Dis. 2014;8(11):e3286 10.1371/journal.pntd.0003286 .
    1. Munisi DZ, Buza J, Mpolya EA, Angelo T, Kinung'hi SM. The efficacy of single-dose versus double-dose praziquantel treatments on Schistosoma mansoni infections: its implication on undernutrition and anaemia among primary schoolchildren in two on-shore communities, northwestern Tanzania. Biomed Res Int. 2017;2017:7035025 10.1155/2017/7035025 .
    1. Nalugwa A, Nuwaha F, Tukahebwa EM, Olsen A. Single versus double dose praziquantel comparison on efficacy and Schistosoma mansoni re-infection in preschool-age children in Uganda: a randomized controlled trial. PLoS Negl Trop Dis. 2015;9(5):e0003796 10.1371/journal.pntd.0003796 .
    1. Knopp S, Ame SM, Hattendorf J, Ali SM, Khamis IS, Bakar F, et al. Urogenital schistosomiasis elimination in Zanzibar: accuracy of urine filtration and haematuria reagent strips for diagnosing light intensity Schistosoma haematobium infections. Parasit Vectors. 2018;11(1):552 10.1186/s13071-018-3136-6 .
    1. Bärenbold O, Garba A, Colley DG, Fleming FM, Haggag AA, Ramzy RMR, et al. Translating preventive chemotherapy prevalence thresholds for Schistosoma mansoni from the Kato-Katz technique into the point-of-care circulating cathodic antigen diagnostic test. PLoS Negl Trop Dis. 2018;12(12):e0006941 10.1371/journal.pntd.0006941 .
    1. Lamberton PH, Kabatereine NB, Oguttu DW, Fenwick A, Webster JP. Sensitivity and specificity of multiple Kato-Katz thick smears and a circulating cathodic antigen test for Schistosoma mansoni diagnosis pre- and post-repeated-praziquantel treatment. PLoS Negl Trop Dis. 2014;8(9):e3139 10.1371/journal.pntd.0003139 .
    1. Mwinzi PN, Kittur N, Ochola E, Cooper PJ, Campbell CH Jr., King CH, et al. Additional evaluation of the point-of-contact circulating cathodic antigen assay for Schistosoma mansoni infection. Frontiers in public health. 2015;3:48 10.3389/fpubh.2015.00048 .
    1. Utzinger J, Becker SL, van Lieshout L, van Dam GJ, Knopp S. New diagnostic tools in schistosomiasis. Clin Microbiol Infect. 2015;21(6):529–42. 10.1016/j.cmi.2015.03.014 .
    1. Colley DG, Binder S, Campbell C, King CH, Tchuem Tchuenté LA, N'Goran EK, et al. A five-country evaluation of a point-of-care circulating cathodic antigen urine assay for the prevalence of Schistosoma mansoni. Am J Trop Med Hyg. 2013;88(3):426–32. 10.4269/ajtmh.12-0639 .
    1. WHO. Report of the WHO Strategic and Technical Advisory Group for Neglected Tropical Diseases. Geneva: World Health Organization, 2015.
    1. Wilson RA, van Dam GJ, Kariuki TM, Farah IO, Deelder AM, Coulson PS. The detection limits for estimates of infection intensity in schistosomiasis mansoni established by a study in non-human primates. Int J Parasitol. 2006;36(12):1241–4. 10.1016/j.ijpara.2006.07.002 .
    1. Koukounari A, Donnelly CA, Moustaki I, Tukahebwa EM, Kabatereine NB, Wilson S, et al. A latent Markov modelling approach to the evaluation of circulating cathodic antigen strips for schistosomiasis diagnosis pre- and post-praziquantel treatment in Uganda. PLoS Comput Biol. 2013;9(12):e1003402 10.1371/journal.pcbi.1003402 .
    1. Botros S, Pica-Mattoccia L, William S, El-Lakkani N, Cioli D. Effect of praziquantel on the immature stages of Schistosoma haematobium. Int J Parasitol. 2005;35(13):1453–7. 10.1016/j.ijpara.2005.05.002 .
    1. N'Goran EK, Utzinger J, N'Guessan AN, Müller I, Zamblé K, Lohourignon KL, et al. Reinfection with Schistosoma haematobium following school-based chemotherapy with praziquantel in four highly endemic villages in Côte d'Ivoire. Trop Med Int Health. 2001;6(10):817–25. 10.1046/j.1365-3156.2001.00785.x .
    1. Bustinduy AL, Waterhouse D, de Sousa-Figueiredo JC, Roberts SA, Atuhaire A, van Dam GJ, et al. Population pharmacokinetics and pharmacodynamics of praziquantel in Ugandan children with intestinal schistosomiasis: higher dosages are required for maximal efficacy. MBio. 2016;7(4). 10.1128/mBio.00227-16 .
    1. Sabah AA, Fletcher C, Webbe G, Doenhoff MJ. Schistosoma mansoni: chemotherapy of infections of different ages. Exp Parasitol. 1986;61(3):294–303. 10.1016/0014-4894(86)90184-0 .
    1. Koné S, Baikoro N, N'Guessan Y, Jaeger FN, Silué KD, Fürst T, et al. Health & Demographic Surveillance System Profile: The Taabo health and demographic surveillance system, Côte d'Ivoire. Int J Epidemiol. 2015;44(1):87–97. 10.1093/ije/dyu221 .
    1. Hoekstra PT, Casacuberta Partal M, Amoah AS, van Lieshout L, Corstjens P, Tsonaka S, et al. Repeated doses of Praziquantel in Schistosomiasis Treatment (RePST)—single versus multiple praziquantel treatments in school-aged children in Côte d'Ivoire: a study protocol for an open-label, randomised controlled trial. BMC Infect Dis. 2018;18(1):662 10.1186/s12879-018-3554-2 .
    1. Casacuberta-Partal M, Hoekstra PT, Kornelis D, van Lieshout L, van Dam GJ. An innovative and user-friendly scoring system for standardised quantitative interpretation of the urine-based point-of-care strip test (POC-CCA) for the diagnosis of intestinal schistosomiasis: a proof-of-concept study. Acta Trop. 2019;199:105150 10.1016/j.actatropica.2019.105150 .
    1. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo. 1972;14:397–400.
    1. Machin D, Campbell MJ, Tan SB, Tan SH. Comparing two independent groups for binary data Sample Size Tables for Clinical Studies: Wiley-Blackwell; 2009. p. 30–41.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. 10.1016/j.jbi.2008.08.010 .
    1. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208 10.1016/j.jbi.2019.103208 .
    1. Coulibaly JT, N'Gbesso YK, Knopp S, N'Guessan NA, Silué KD, van Dam GJ, et al. Accuracy of urine circulating cathodic antigen test for the diagnosis of Schistosoma mansoni in preschool-aged children before and after treatment. PLoS Negl Trop Dis. 2013;7(3):e2109 10.1371/journal.pntd.0002109 .
    1. Walker M, Churcher TS, Basáñez MG. Models for measuring anthelmintic drug efficacy for parasitologists. Trends Parasitol. 2014;30(11):528–37. 10.1016/j.pt.2014.08.004 .
    1. Walker M, Mabud TS, Olliaro PL, Coulibaly JT, King CH, Raso G, et al. New approaches to measuring anthelminthic drug efficacy: parasitological responses of childhood schistosome infections to treatment with praziquantel. Parasit Vectors. 2016;9:41 10.1186/s13071-016-1312-0 .
    1. Olliaro PL, Vaillant M, Diawara A, Coulibaly JT, Garba A, Keiser J, et al. Toward measuring Schistosoma response to praziquantel treatment with appropriate descriptors of egg excretion. PLoS Negl Trop Dis. 2015;9(6):e0003821 10.1371/journal.pntd.0003821 .
    1. WHO. Assessing the efficacy of anthelminthic drugs against schistosomiasis and soil-transmitted helminthiases Geneva: World Health Organization; 2013.
    1. Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008;21(6):659–67. 10.1097/QCO.0b013e328318978f .
    1. RMD. Technical Brochure—Rapid test for qualitative detection of: Bilharzia (Schistosomiasis). .
    1. Greter H, Krauth SJ, Ngandolo BN, Alfaroukh IO, Zinsstag J, Utzinger J. Validation of a point-of-care circulating cathodic antigen urine cassette test for Schistosoma mansoni diagnosis in the Sahel, and potential cross-reaction in pregnancy. Am J Trop Med Hyg. 2016;94(2):361–4. 10.4269/ajtmh.15-0577
    1. Kittur N, Castleman JD, Campbell CH Jr., King CH, Colley DG. Comparison of Schistosoma mansoni prevalence and intensity of infection, as determined by the circulating cathodic antigen urine assay or by the Kato-Katz fecal assay: a systematic review. Am J Trop Med Hyg. 2016;94(3):605–10. 10.4269/ajtmh.15-0725 .
    1. Clements MN, Corstjens P, Binder S, Campbell CH Jr., de Dood CJ, Fenwick A, et al. Latent class analysis to evaluate performance of point-of-care CCA for low-intensity Schistosoma mansoni infections in Burundi. Parasit Vectors. 2018;11(1):111 10.1186/s13071-018-2700-4 .
    1. Sousa MS, van Dam GJ, Pinheiro MCC, de Dood CJ, Peralta JM, Peralta RHS, et al. Performance of an ultra-sensitive assay targeting the circulating anodic antigen (CAA) for detection of Schistosoma mansoni infection in a low endemic area in Brazil. Front Immunol. 2019;10(682).
    1. Lodh N, Mwansa JC, Mutengo MM, Shiff CJ. Diagnosis of Schistosoma mansoni without the stool: comparison of three diagnostic tests to detect Schistosoma [corrected] mansoni infection from filtered urine in Zambia. Am J Trop Med Hyg. 2013;89(1):46–50. 10.4269/ajtmh.13-0104 .
    1. Meurs L, Brienen E, Mbow M, Ochola EA, Mboup S, Karanja DM, et al. Is PCR the next reference standard for the diagnosis of Schistosoma in stool? A comparison with microscopy in Senegal and Kenya. PLoS Negl Trop Dis. 2015;9(7):e0003959 10.1371/journal.pntd.0003959 .
    1. Corstjens PL, De Dood CJ, Kornelis D, Fat EM, Wilson RA, Kariuki TM, et al. Tools for diagnosis, monitoring and screening of Schistosoma infections utilizing lateral-flow based assays and upconverting phosphor labels. Parasitology. 2014;141(14):1841–55. 10.1017/S0031182014000626 .
    1. Utzinger J, Booth M, N'Goran EK, Müller I, Tanner M, Lengeler C. Relative contribution of day-to-day and intra-specimen variation in faecal egg counts of Schistosoma mansoni before and after treatment with praziquantel. Parasitology. 2001;122(05):537–44.
    1. Engels D, Sinzinkayo E, Gryseels B. Day-to-day egg count fluctuation in Schistosoma mansoni infection and its operational implications. Am J Trop Med Hyg. 1996;54(4):319–24. 10.4269/ajtmh.1996.54.319 .
    1. Colley DG, Andros TS, Campbell CH Jr. Schistosomiasis is more prevalent than previously thought: what does it mean for public health goals, policies, strategies, guidelines and intervention programs? Infect Dis Poverty. 2017;6(1):63 10.1186/s40249-017-0275-5 .
    1. Haggag AA, Rabiee A, Abd Elaziz KM, Campbell CH, Colley DG, Ramzy RMR. Thirty-day daily comparisons of Kato-Katz and CCA assays of 45 Egyptian children in areas with very low prevalence of Schistosoma mansoni. Am J Trop Med Hyg. 2019;100(3):578–83. 10.4269/ajtmh.18-0829 .
    1. van Dam GJ, Bogitsh BJ, van Zeyl RJ, Rotmans JP, Deelder AM. Schistosoma mansoni: in vitro and in vivo excretion of CAA and CCA by developing schistosomula and adult worms. J Parasitol. 1996;82(4):557–64. .
    1. Lamberton PHL, Faust CL, Webster JP. Praziquantel decreases fecundity in Schistosoma mansoni adult worms that survive treatment: evidence from a laboratory life-history trade-offs selection study. Infect Dis Poverty. 2017;6(1):110 10.1186/s40249-017-0324-0 .
    1. Wilson S, Jones FM, van Dam GJ, Corstjens PL, Riveau G, Fitzsimmons CM, et al. Human Schistosoma haematobium antifecundity immunity is dependent on transmission intensity and associated with immunoglobulin G1 to worm-derived antigens. J Infect Dis. 2014;210(12):2009–16. 10.1093/infdis/jiu374 .
    1. King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet. 2005;365(9470):1561–9. 10.1016/S0140-6736(05)66457-4
    1. King CH. It's time to dispel the myth of "asymptomatic" schistosomiasis. PLoS Negl Trop Dis. 2015;9(2):e0003504 10.1371/journal.pntd.0003504 .
    1. Colley DG, Secor WE. Immunology of human schistosomiasis. Parasite Immunol. 2014;36(8):347–57. 10.1111/pim.12087 .
    1. Kildemoes AO, Vennervald BJ, Tukahebwa EM, Kabatereine NB, Magnussen P, de Dood CJ, et al. Rapid clearance of Schistosoma mansoni circulating cathodic antigen after treatment shown by urine strip tests in a Ugandan fishing community—relevance for monitoring treatment efficacy and re-infection. PLoS Negl Trop Dis. 2017;11(11):e0006054 10.1371/journal.pntd.0006054 .
    1. Raso G, N'Goran EK, Toty A, Luginbühl A, Adjoua CA, Tian-Bi NT, et al. Efficacy and side effects of praziquantel against Schistosoma mansoni in a community of western Côte d'Ivoire. Trans R Soc Trop Med Hyg. 2004;98(1):18–27. 10.1016/s0035-9203(03)00003-8 .
    1. Olds GR, King C, Hewlett J, Olveda R, Wu G, Ouma J, et al. Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. J Infect Dis. 1999;179(4):996–1003. 10.1086/314686 .

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa